By Denny Jacob
Shares of GeneDx Holdings shot up 24% following higher-than-expected revenue in its fourth quarter.
Shares were trading around $95. Over the last year, the stock is up nearly 1800%.
The patient health intelligence company recorded revenue of $95.3 million, up 64% from $58.1 million in the prior-year period. Analysts polled by FactSet had expected $82.2 million.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 18, 2025 10:14 ET (15:14 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。